参考文献/References:
[1] McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[2] Vardeny O,Claggett B,Packer M,et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction:the PARADIGM-HF trial[J]. Eur J Heart Fail,2016,18(10):1228-1234.
[3] Martens P,Nuyens D,Rivero-Ayerza M,et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol,2019,108(10):1074-1082.
[4] Torrado J,Cain C,Mauro AG,et al. Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits[J]. J Am Coll Cardiol,2018,72(19):2342-2356.
[5] Rezq A,Saad M,El Nozahi M. Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol,2021,143:7-13.
[6] Zhang Y,Wu Y,Zhang K,et al. Benefits of early administration of sacubitril/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention[J]. Coron Artery Dis, 2021,32(5):427-431.
[7] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
[8] Packer M,Anker SD,Butler J,et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med,2020,383(15):1413-1424.
[9] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[10] McMurray JJV,Solomon SD,Inzucchi SE,et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2019,381(21):1995-2008.
[11] Zelniker TA,Wiviott SD,Raz I,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet,2019,393(10166):31-39.
[12] Yan Y,Liu B,Du J,et al. SGLT2i versus ARNI in heart failure with reduced ejection fraction:a systematic review and meta-analysis[J]. ESC Heart Fail,2021 ,8(3):2210-2219.
[13] Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2020,382(20):1883-1893.
[14] Zannad F,McMurray JJ,Krum H,et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med,2011,364(1):11-21.
[15] Pitt B,Zannad F,Remme WJ,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure[J]. N Engl J Med,1999,341(10):709-717.
[16] Liu LC,Schutte E,Gansevoort RT,et al. Finerenone:third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease[J]. Expert Opin Investig Drugs,2015,24(8):1123-1135.
[17] Pitt B,Kober L,Ponikowski P,et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease:a randomized,double-blind trial[J]. Eur Heart J,2013,34(31):2453-2463.
[18] Bakris GL,Agarwal R,Chan JC,et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy:a randomized clinical trial[J]. JAMA,2015,314(9):884-894.
[19] Filippatos G,Anker SD,B?hm M,et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease[J]. Eur Heart J,2016,37(27):2105-2114.
[20] Nanas JN,Matsouka C,Karageorgopoulos D,et al. Etiology of anemia in patients with advanced heart failure[J]. J Am Coll Cardiol,2006,48(12):2485-2489.
[21] Opasich C,Cazzola M,Scelsi L,et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure[J]. Eur Heart J,2005,26(21):2232-2237.
[22] Anker SD,Comin Colet J,Filippatos G,et al. Ferric carboxymaltose in patients with heart failure and iron deficiency[J]. N Engl J Med,2009,361(25):2436-2448.
[23] Ponikowski P,Kirwan BA,Anker SD,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure:a multicentre,double-blind,randomised,controlled trial[J]. Lancet,2020,396(10266):1895-1904.
[24] Teerlink JR,Felker GM,McMurray JJ,et al. Chronic oral study of myosin activation to increase contractility in heart failure(COSMIC-HF):a phase 2,pharmacokinetic,randomised,placebo-controlled trial[J]. Lancet,2016,388(10062):2895-2903.
[25] Teerlink JR,Diaz R,Felker GM,et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure[J]. N Engl J Med,2021,384(2):105-116.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(11):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(11):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(11):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]